U.S. Events Finder

See what sports, music or family events are going on there. We show you events of all kinds: make your selection from the right-hand navigation bar. After you make your selection, please click Apply button.

Music

Performing

Media

Social

Education

Commercial

Festivals

Sports

Other

Comedy

Politics

Family

Conference

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

Epigenetics, Development and Human Disease (A1)

Jan 5-10, 2009 at Beaver Run Resort, Breckenridge Colorado United States

This meeting aims to provide a stimulating forum for exploring the epigenetic control of genome function illustrated through the regulation of a variety of biological processes in a range of model organisms. The role of factors influencing chromatin organization and chromosome architecture, and the dynamic changes in epigenetic state that regulate development, are two well-established but fast-moving areas that will be covered. The dynamic nature of epigenetic states renders them both adaptable and vulnerable; this will be explored in sessions considering the influence of the environment on epigenetic control, and the causes and consequences of epigenetic change in disease. We anticipate that the data presented will

Omics Meets Cell Biology (B2)

Jan 25-30, 2009 at Beaver Run Resort, Breckenridge Colorado United States

Apart from deciphering the genomic sequences of hundreds of species, the (human) genome project has catalyzed a wave of technological innovation that is unprecedented in the life sciences. Among its most important products are a number of assays or technologies for the quantitative, global and high throughput analysis of the genome, the molecules derived from the genome and their interactions. These technologies are colloquially described as xe2x80x9cOMICSxe2x80x9d technologies. The data sets generated by OMICS technologies represent a unique resource for biologists. They have also raised a number of challenging technical and conceptual issues, the solutions to which will ultimately determine the impact of OMICS technologies on biology. These include the error models, completeness and reproducibility of large scale data sets, the question whether and how

Drug Discovery for Protozoan Parasites (D2)

Mar 22-26, 2009 at Beaver Run Resort, Breckenridge Colorado United States

The discovery and development of new drugs for protozoan parasites has rapidly expanded to include multidisciplinary approaches from academia, government, and industry. Public-private partnerships have focused efforts on translational research and as a result, new drugs have been advanced into clinical evaluation. Unfortunately, development of several promising new drugs has recently been terminated in clinical trials thus leaving a sparse pipeline of new chemical entities that have potential for registration in the next few years. Importantly, the need for effective new drugs for major human parasitic diseases (malaria, leishmaniasis, and trypanosomiasis) is growing and concerns over antimalarial resistance to artemisinin-based drugs are building. This meeting will bring together chemists, biologists, pharmacologists, and clinicians to find solutions to accelerate drug discovery efforts. Key problems to be addressed include identification

U.S. States

• Vermont
• Maryland
• Florida
• District Of Columbia
• New York
• Hawaii
• Washington
• Mississippi

View all States in USA

Cities in Colorado

• La Salle (CO)
• Hamilton (CO)
• Lazear (CO)
• Fairplay (CO)
• Monarch (CO)
• Hot Sulphur Springs (CO)
• Alma (CO)
• Hygiene (CO)

View all cities in Colorado

States in USA

Hide States

Cities in Colorado

Hide Cities